What Латикорт Treats: Main Uses and Benefits

The primary role of Латикорт (topical Hydrocortisone) is to provide symptomatic relief across therapeutic domains where skin inflammation and intense itching create noticeable physiological strain. The medication is used in conditions marked by heightened symptoms that interfere with daily functioning. It is commonly used to help with the redness, swelling, itching, and discomfort associated with various skin conditions.

Латикорт is commonly used across conditions presenting with inflammatory or irritative processes, such as Eczema, certain forms of Psoriasis, Contact Dermatitis, and reactions to Insect Bites. It is applied in clinical settings that involve acute or unstable symptom patterns, primarily addressing pronounced Redness and Swelling that accompany disease flare-ups. This symptomatic assistance helps patients cope more steadily with difficult episodes and contributes to improved day-to-day comfort during symptomatic periods. The medication is relevant when supportive symptom management is appropriate in contexts marked by increased discomfort. This symptomatic relief helps ease the overall symptom burden and provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Inflammation
Primary symptoms addressed	Redness, Swelling, Itching, Burning
Therapeutic benefit	Contributes to easing the overall symptom load and assists with maintaining functional stability
Common context	Acute flare-ups of Eczema and allergic reactions

Regulatory References

1. NIH MedlinePlus overview of Hydrocortisone topical

This section outlines the official eligibility and exclusion criteria for Латикорт (Hydrocortisone Butyrate) based strictly on government regulatory documents.

Populations Excluded or Contraindicated

Contraindications include patients with a documented hypersensitivity (allergy) to the active substance or any other component of the formulation. The medicine is also typically contraindicated for use on skin areas affected by specific conditions, such as:

• Untreated infections caused by viruses (e.g., Herpes simplex, Varicella), fungi, or bacteria.
• Acne vulgaris, rosacea, or perioral dermatitis.
• Ulcerous skin lesions.

Restricted and Conditional Use

Use is restricted in several patient groups due to the risk of increased systemic absorption, which can lead to body-wide side effects:

• Infants and Children: Pediatric patients, especially those under 3 months of age, have not had safety established for certain formulations. Use in children should be limited to the least amount and shortest duration necessary.
• Pregnancy and Lactation: Use during pregnancy is conditional; it should only be used if the potential benefit outweighs the potential risk to the fetus, and it must not be used extensively or for prolonged periods. Caution is advised when breastfeeding.
• Application Constraints: The drug should not be used under occlusive dressings (including tight diapers) or applied over large surface areas or on the face, underarms, or groin unless specifically directed by a healthcare provider, as this increases systemic absorption.

Interactions with other medicines and products

The official regulatory documents for Латикорт (Topical Hydrocortisone) indicate a profile defined primarily by the absence of established pharmacokinetic interactions with other medicinal products.

Interaction scope	Official Regulatory Information
Interacting substances	None are specifically listed for drug-drug, drug-food, or herbal product interactions, as established interactions have not been documented for the topical formulation.
Mechanistic basis	The documented interaction profile relies on systemic absorption of the active substance, which can lead to a pharmacodynamic interaction with the body’s Hypothalamic-Pituitary-Adrenal (HPA) axis.
Population notes	Pediatric patients are noted to have increased susceptibility to the systemic outcome (HPA axis suppression) due to a higher skin surface area to body mass ratio.

---

Interaction classifications (high-level)

The potential outcome of augmented exposure (HPA axis suppression) is officially classified as a serious systemic effect. The primary constraints are method-of-use dependent, as application practices directly modulate the absorption risk.

Official interaction statements:

• No known drug-drug interactions are established for the topical Hydrocortisone formulation.
• The risk of the systemic effect is formally increased by occlusive dressings, application to large surface areas, and prolonged duration of use.
• No mandatory timing-based separation rules are documented for co-administered medicines.

Connection to the overall interaction profile:

Regulatory documents define this product’s interaction structure by the explicit absence of specific co-administered interacting substances, shifting the entire focus onto the conditional risk of systemic absorption. This means the chief consideration is avoiding application methods that augment exposure, a restriction that is clearly defined in the governmental labels.

Receptor Agonism and Gene Transcription Control

The active ingredient of Латикорт acts as an agonist for the Cytosolic Glucocorticoid Receptor ( GR), initiating the primary mechanism. The resulting drug-receptor complex translocates into the cell nucleus and modulates gene expression through transactivation (inducing anti-inflammatory proteins) and transrepression (suppressing pro-inflammatory transcription factors, notably NF-kappa B). This core transcriptional control reduces the cell's capacity to produce inflammatory signals.

---

Blocking the Arachidonic Acid Cascade

A key consequence of this gene modulation is the increased synthesis of the protein Lipocortin-1. Lipocortin-1 then acts to indirectly inhibit the enzyme Cytosolic Phospholipase A2 ( cPLA2). This step is central because cPLA2 is required to release Arachidonic Acid, the precursor to lipid mediators like prostaglandins and leukotrienes. This mechanism effectively halts the production of these pro-inflammatory eicosanoids, leading to a reduction in the formation of edema and the activity of pruritogenic mediators.

---

Local Vascular and Immune Modulation

This cascade, along with direct vascular effects, results in local vasoconstriction, which narrows superficial capillaries and reduces their permeability. Physiologically, this action decreases the leakage of plasma fluid and immune cells into the surrounding tissue, contributing to a reduction in local erythrocyte and plasma exudation.

The administration of Латикорт (topical Hydrocortisone) is strictly limited to the topical route, meaning the preparation—such as a cream, ointment, or emulsion—is applied directly to the affected skin surface. The concentration of the active ingredient typically ranges from 0.5% to 2.5% USP in available forms. The standard application protocol requires applying a thin film of the product to the affected area and gently rubbing it in. It is essential that Латикорт remains for external use only, avoiding contact with the eyes, mouth, or other mucous membranes.

The most common labeled administration schedule involves application two to four times daily. However, the use of topical corticosteroids is intended to be short-term, as the safety and efficacy of usage exceeding four weeks have not been definitively established in some contexts. The usage instructions strictly prohibit covering or wrapping the treated skin with bandages or any occlusive dressings unless specifically advised by a healthcare provider for recalcitrant conditions. For pediatric patients, a key restriction requires that tight-fitting diapers or plastic pants must be avoided when treating the diaper area. For treatment courses that are prolonged, a gradual reduction in application frequency (tapering) should be initiated when discontinuing the product.

Research Evidence / Overview of Studies for Латикорт

This section provides an overview of the scientific research that exists for topical Hydrocortisone ( Латикорт) and related low-potency formulations. It describes how studies were conducted, what outcomes were measured, and where the current evidence has limitations. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

---

Evidence for Use in Atopic Dermatitis (Eczema)

Research exploring how symptoms change over time in patients with Eczema frequently uses gold-standard methods like Randomized Controlled Trials (RCTs) and Systematic Reviews that combine data from many different studies. The research examined changes in the condition using scores like the Eczema Area and Severity Index (EASI) and the Investigator Global Assessment (IGA). Additionally, studies monitored patient-reported outcomes describing perceived discomfort, focusing on the intensity of Itching (Pruritus) and the level of Sleep Disturbance.

Studies reported how symptoms evolved in the observed populations during treatment intervals that typically lasted between two and four weeks. Some trials described patterns observed when the medicine was used intermittently, designed to explore whether the application schedule was associated with a lower frequency of symptom return. Research contributes to the broader evidence landscape related to managing inflammatory skin conditions.

Despite the existence of a high volume of evidence, long-term effects are not fully established for continuous application, as the majority of trials focus on short-term symptom relief. Furthermore, evidence quality varies across studies, with some older research exhibiting limited quality and inconsistencies in how outcomes were measured.

---

Evidence for Use in Psoriasis and Other Inflammatory Skin Conditions

Topical Hydrocortisone was studied for conditions involving periods of heightened symptoms, including Psoriasis and other conditions marked by functional limitations. Research related to this class of medicine often comes from Systematic Reviews and RCTs that evaluated outcomes linked to inflammatory or irritative states. Studies monitored physiological strain by measuring the severity of psoriatic plaques. Regulatory bodies also utilize specific laboratory-based measures, such as the Vasoconstrictor Assay, which is used to determine the potency classification of the formulation.

Studies report how symptoms evolved in the observed populations during periods of increased symptom activity. The research provides insight into short-term changes and contributes to understanding symptom patterns in acute or disruptive episodes.

However, the certainty remains low regarding the direct use of the low-potency Hydrocortisone formulation compared to the wealth of data available for higher-potency topical steroids within the Psoriasis research space. The body of evidence contains limited comparative data regarding the specific outcomes of this low-potency agent. Also, the findings were mixed regarding the standardization of outcome measurement across all clinical development trials.

Key Studies & References Hydrocortisone (Topical Route) - MedlinePlus Drug Information

Common questions about Латикорт (FAQ)

---

Q: What is the difference between Laticort cream and ointment?

Laticort cream and ointment differ in their base composition. The cream uses a hydrophilic base and is generally preferred for moist skin conditions, while the ointment uses a more lipophilic (fatty) base. Official product information describes the ointment as typically chosen for treating very dry or scaly skin areas.

Q: What happens if I suddenly stop using Laticort?

Stopping long-term, intensive use of topical corticosteroids abruptly carries the risk of developing Topical Steroid Withdrawal (TSW), which may manifest as burning and significant redness of the skin upon cessation. Official documentation states that a gradual reduction in application frequency (tapering) should be initiated when discontinuing the product.

Q: Is Laticort prescribed to children? If so, from what age?

The safety of Laticort has not been established for use in infants under 3 months of age for certain formulations. Children are generally more susceptible to the medicine being absorbed into the body (systemic absorption). Official labeling restricts the use of the product in pediatric patients to the least amount and shortest duration necessary.

Q: Can Laticort be used if the skin is dry?

Yes, Laticort can be used on dry skin. Official documents indicate that the ointment formulation is typically selected for treating dry or scaly areas. This preference is due to the ointment's base composition, which helps to moisturize the skin while delivering the active ingredient.

Q: Why does the leaflet mention 'withdrawal syndrome' with long-term use?

The term 'withdrawal syndrome' (TSW) is included in product information due to regulatory warnings about the risk of adverse reactions upon stopping prolonged use. This condition can include symptoms like skin burning and rebound redness. To help mitigate this risk, official labels suggest a gradual reduction in the application frequency (tapering) should be initiated.

Q: Does Laticort affect the immune system?

Laticort's primary action is to modulate local inflammatory and immune reactions directly within the skin, suppressing the mediators that cause redness and swelling. A significant effect on the body's overall immune system (systemic impact) is only considered a risk if substantial absorption occurs due to prolonged or extensive use.

Q: Can Laticort get into the bloodstream through the skin?

Yes, the active ingredient in Laticort can be absorbed through the skin and enter the bloodstream. The extent of this absorption is highly variable and depends on factors such as the integrity of the skin barrier, the surface area treated, and whether occlusive dressings (like bandages or tight diapers) are used.

Q: What should I do if I accidentally applied Laticort to a mucous membrane?

Official instructions strictly prohibit contact with mucous membranes, including the eyes and mouth. Regulatory documents state that consultation with a healthcare provider or pharmacist is required if accidental contact occurs, as the labels do not contain specific emergency rinsing instructions for patients.

Q: What is in the composition of Laticort cream?

Laticort cream contains the active ingredient, Hydrocortisone Butyrate. It also contains several inactive ingredients, or excipients, that form the cream's base. These typically include substances like mineral oil, white petrolatum, cetostearyl alcohol, citric acid, and sodium citrate, as listed in the official composition documents.

Q: Can Laticort cause addiction/dependency?

With long-term, intensive use, a physical change known as 'withdrawal syndrome' may occur when the medicine is stopped, which some users refer to as dependency or habituation. Official documents address this risk by including instructions for gradual reduction in use.

Q: Is Laticort compatible with alcohol?

Official regulatory documents do not list any established contraindications, warnings, or timing restrictions regarding the co-consumption of alcohol while using topical Laticort. The interaction profile for this formulation is primarily focused on the potential for systemic absorption risks, rather than interactions with ingested substances.

Q: Can Laticort be used together with other creams?

Official regulatory documents do not specify mandatory timing separation rules for co-administered topical products. Furthermore, no known drug-drug interactions are established for this topical formulation.

Q: Can Laticort be used on open wounds?

The official label contraindicates the use of Laticort on ulcerous skin lesions. Use on any broken skin, including open wounds or cracks, may lead to increased systemic absorption. This information is derived from the product's official regulatory warnings.

Q: Is Laticort available by prescription?

Yes, official regulatory labeling indicates that Laticort (Hydrocortisone Butyrate 0.1%) is classified as a prescription-only medicine (Rx only). This classification means it requires a valid prescription from a licensed healthcare provider.

Q: What is Laticort's strength classification (weak, moderate)?

The potency of topical corticosteroids is officially classified using a standardized method called the vasoconstrictor assay. Laticort, which contains Hydrocortisone Butyrate 0.1%, is generally classified as a mid-strength (Group V) topical corticosteroid.

Q: Can Laticort cause pigment spots?

Official regulatory documents detailing the product's adverse reaction profile do not include skin pigmentation changes (either darkening or lightening of the skin) in the list of commonly or rarely documented side effects. The documented local side effects focus on issues like skin atrophy and stretch marks.

Q: Why shouldn't Laticort be used if there is skin tuberculosis?

Laticort is contraindicated for use on skin areas affected by untreated infections, including those caused by bacteria, fungi, or viruses. The contraindication is due to the risk that the use of a steroid may worsen the course of untreated bacterial infections, such as skin tuberculosis.

Q: If Laticort doesn't help, when should I see a doctor?

Official information indicates that consultation with a physician is necessary if the skin symptoms do not show improvement within a short period of time, as indicated in the treatment plan, or if local irritation or signs of side effects occur.

Q: Does Laticort affect the ability to drive a car?

Official regulatory data sheets indicate that the topical application of Laticort is not expected to affect the patient’s ability to drive vehicles or operate machinery. The influence on cognitive function or alertness is considered unlikely.

How to Store and Dispose of Латикорт (Hydrocortisone Topical)

The official labeling for Латикорт defines specific storage and handling requirements necessary to maintain product integrity and stability. The medication must be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from freezing, excessive heat, moisture, and direct light.

Official Storage and Handling Rules

Storage Component	Requirement
Temperature	Store at controlled room temperature; Do not freeze
Protection	Keep away from excess heat, light, and moisture
Container	Keep in original container and tightly closed
Safety	Store out of the sight and reach of children

All unused or expired Латикорт must be discarded according to local regulations. The product should not be disposed of by flushing it down the toilet or pouring it into a drain.